This not yet recruiting study focuses on depression and currently lists sites or participation links in China.
This study exists to compare options and see whether ketamine treatment offers something meaningfully different. For people living with Depression, that matters because care needs to work in daily life, not just in theory. The findings could guide better understanding and future care, and taking part helps build that evidence for others.
The official record suggests in-person participation through a hospital, with sites including First Medical center of Chinese PLA General Hospital in Beijing. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and meeting the main study requirements, while common reasons not to take part include active substance or alcohol problems that could affect the results and major medical issues that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordTaking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in China.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com